PRELUDE THERAPEUTICS INC Operating Lease Cost
PRELUDE THERAPEUTICS INC (PRLD) reported Operating Lease Cost of $1.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC operating lease, cost for the quarter ending 2026-06-30 was $1.10M, a 10.00% increase year-over-year.
- PRELUDE THERAPEUTICS INC operating lease, cost for the quarter ending 2026-03-31 was $1.10M, a 0.00% change year-over-year.
- PRELUDE THERAPEUTICS INC operating lease, cost for the quarter ending 2025-09-30 was $1.10M, a 8.33% decline year-over-year.
- PRELUDE THERAPEUTICS INC operating lease, cost for the quarter ending 2025-06-30 was $1.00M, a 52.38% decline year-over-year.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.10M 10-Q · filed 2026-08-11 | $2.20M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $1.10M 10-Q · filed 2026-05-12 | ||||
| 2025-09-30 | $1.10M 10-Q · filed 2025-11-12 | $2.10M derived: sum of 2 quarters · filed 2026-08-11 | $3.20M 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $1.00M 10-Q · filed 2026-08-11 | $2.10M 10-Q · filed 2026-08-11 | $1.00M 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | $1.10M 10-Q · filed 2026-05-12 | ||||
| 2024-09-30 | $1.20M 10-Q · filed 2025-11-12 | $3.30M derived: sum of 2 quarters · filed 2025-11-12 | $3.30M 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $2.10M 10-Q · filed 2025-08-14 | $1.00M 10-Q · filed 2024-08-12 | $2.10M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $1.10M 10-Q · filed 2025-05-06 | ||||
| 2023-09-30 | $500.00K 10-Q · filed 2024-11-06 | $900.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.60M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-12 | $900.00K 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |